Impaired function of gamma-delta lymphocytes in melanoma patients (Q39317720)

11 September 2017

title

Impaired function of gamma-delta lymphocytes in melanoma patients (English)

1 reference

11 September 2017

0 references

Iacopo Petrini

1

1 reference

11 September 2017

Simone Pacini

2

1 reference

11 September 2017

Sara Galimberti

3

1 reference

11 September 2017

Maria R Taddei

4

1 reference

11 September 2017

Antonella Romanini

5

1 reference

11 September 2017

Mario Petrini

6

1 reference

11 September 2017

publication date

1 April 2011

1 reference

European Journal of Clinical Investigation

11 September 2017

published in

1 reference

11 September 2017

volume

41

1 reference

11 September 2017

issue

11

1 reference

11 September 2017

page(s)

1186-1194

1 reference

11 September 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Spontaneous regression of melanoma may offer insight into cancer immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Gamma delta T cells provide an early source of interferon gamma in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Role of gammadelta T cells in protecting normal airway function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Immunosurveillance and immunoregulation by gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Selective lysis of the autologous tumor by δTCS1+ γ/δ+ tumor-infiltrating lymphocytes from human lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Heterogeneity of T-cell clones infiltrating primary malignant melanomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Regulation of cutaneous malignancy by gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Alpha/beta- and gamma/delta TCR(+) lymphocyte infiltration in necrotising choroidal melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Natural and synthetic non-peptide antigens recognized by human gamma delta T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Circulating gammadelta T cells in young/adult and old patients with cutaneous primary melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

CD57+ T lymphocytes and functional immune deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2011.02524.X

10.1111/J.1365-2362.2011.02524.X

21 January 2018

Identifiers

DOI

1 reference

release_qa2nr5nbivhf7dqe3b2i57uxu4

11 September 2017

Fatcat ID

0 references

1 reference